Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Bayer & Exscientia collaborate to leverage potential of AI in cardiovascular & oncology drug discovery

09 Jan 2020

Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. Under terms of the agreement, Exscientia will initially work on three projects with targets agreed between both parties. Exscientia may be eligible to receive up to €240 Million, including... Read more

Intuitive Announces New UK Headquarters in Oxford

04 Sep 2019

OXFORD, England–Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the opening of its United Kingdom and Republic of Ireland headquarters and training suite at Oxford Science Park’s Schrödinger Building. “Oxford is internationally renowned for medical and scientific innovation and we are proud to expand our collaboration with this community that we think... Read more

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

27 Jun 2019

27th June 2019 ‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team ‒ ‒ Acquisition driven by lead product Axumin® (fluciclovine F 18), a novel molecular imaging agent for use with PET imaging to detect recurrent prostate cancer, and a robust pipeline ‒ ‒ Combined business will leverage Bracco’s diagnostic modalities, global competencies, portfolio and financial resources ‒ BURLINGTON,... Read more

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

16 Apr 2019

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual... Read more

Blue Earth Diagnostics celebrates five year anniversary

06 Mar 2019

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs... Read more

News